29.01.2024 - WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) - TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of ... Seite 1